Compare Adaptive Biotechnologies Corp (ADPT) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs AST SpaceMobile Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while AST SpaceMobile Inc trades at $74.16 (market cap $22.17B). The key difference: AST SpaceMobile Inc is far larger — about 6.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | ASTS | |
|---|---|---|
Market Cap | $3.33B | $22.17B |
Sector | Health | Media |
52-Week High | $22.37 | $133.09 |
52-Week Low | $10.24 | $36.91 |
Enterprise Value | $3.19B | $22.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AST SpaceMobile (ASTS) trades at $74.21, down 12.83% in the last session amid a broader space stock selloff. The stock shows bearish technical signals with negative earnings surprises and deeply negative profitability margins. Recent news highlights satellite launch progress and competitive pressures from SpaceX, while cash flow remains heavily dependent on financing activities to fund operations and capital expenditures.
Outlook remains speculative with high execution risk; revenue growth is overshadowed by persistent losses and cash burn. Analyst consensus is mixed with a $84 price target offering potential upside, but investors face significant dilution risk and competitive threats in the nascent satellite broadband market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
